CAS625115-55-1 利奧西呱 99%+ SYNTHBIO
Riociguat (Synonyms: 利奧西呱; BAY 632521)
Riociguat (BAY 632521) 是一種可口服的可溶性鳥苷酸環化酶 (sGC) 刺激劑，常用於研究肺動脈高壓癥。
Riociguat Chemical Structure
CAS No. : 625115-55-1
625115-55-1
le data-draft-node="block" data-draft-type="table" data-size="normal" data-row-style="normal">[1]
| 生物活性 | Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension. |
|---|---|
| IC50 & Target | sGC[1] |
| 體外研究(In Vitro) | Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100 μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism[1]. Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes[2].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 體內研究(In Vivo) | Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats[1].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
<table data-draft-node="block" data-draft-type="table" data-size="normal" data-row-style="normal">[1]
| 生物活性 | Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension. |
|---|---|
| IC50 & Target | sGC[1] |
| 體外研究(In Vitro) | Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100 μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism[1]. Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes[2].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 體內研究(In Vivo) | Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats[1].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
[2]
| 生物活性 | Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension. |
|---|---|
| IC50 & Target | sGC[1] |
| 體外研究(In Vitro) | Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100 μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism[1]. Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes[2].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 體內研究(In Vivo) | Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats[1].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 生物活性 | Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension. |
|---|---|
| IC50 & Target | sGC[1] |
| 體外研究(In Vitro) | Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100 μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism[1]. Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes[2].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 體內研究(In Vivo) | Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats[1].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
<table data-draft-node="block" data-draft-type="table" data-size="normal" data-row-style="normal">[1]
| 生物活性 | Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension. |
|---|---|
| IC50 & Target | sGC[1] |
| 體外研究(In Vitro) | Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100 μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism[1]. Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes[2].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 體內研究(In Vivo) | Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats[1].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 生物活性 | Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension. |
|---|---|
| IC50 & Target | sGC[1] |
| 體外研究(In Vitro) | Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100 μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism[1]. Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes[2].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| 體內研究(In Vivo) | Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats[1].MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
ble data-draft-node="block" data-draft-type="table" data-size="normal" data-row-style="normal">625115-55-1le data-draft-node="block" data-draft-type="table" data-size="normal" data-row-style="normal">
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
SYNTHBIO 是致力於從事生命科學研究和提供高質量的生物技術外包服務公司（CRO），主營多肽及小分子等化合物定制合成，同時還擁有自己開發的細胞株、菌株等產品，並承接相關的技術服務以及品牌（細胞、菌株、蛋白、抗體、耗材、儀器）產品。
24小時保姆式服務售前售後（QQ/微信/電話/郵件）汪亞南
天地合氣，萬物自生。